定坤丹联合芬吗通治疗围绝经期综合征疗效和对性激素水平影响

Effect of Dingkundan combined with femoston on perimenopausal syndrome and sex hormone level

目的:探讨定坤丹联合芬吗通对围绝经期综合征(PMS)患者治疗疗效及对性激素水平影响。方法:选择2020年1月-2021年12月本院收治的PMS患者102例,按随机表法分为对照组(n=51)与研究组(n=51)。对照组给予芬吗通片1片/次,1次/d,4周为1个疗程,前14 d口服红色片,后14 d口服黄色片;研究组在对照组基础上口服定坤丹,2次/d,1/2丸/次。两组治疗周期12周。比较两组治疗疗效;治疗前与治疗12周匹兹堡睡眠质量指数量表(PSQI)评分、Kupperman绝经指数(KMI)评分、性激素水平、围绝经期生活质量量表(MENQOL)评分。结果:研究组和对照组总有效率分别为94.12%和76.47%(P<0.05)。两组治疗前PMS患者PSQI评分和KMI评分比较无明显差异(P>0.05);两组治疗12周PMS患者PSQI评分和KMI评分低于治疗前(P<0.05);研究组治疗12周PMS患者PSQI评分和KMI评分低于对照组(P<0.05)。两组治疗前PMS患者血清雌二醇(E2)、卵泡刺激素(FSH)和黄体生成素(LH)水平比较无明显差异(P>0.05);两组治疗12周PMS患者血清E2水平高于治疗前,而PMS患者FSH和LH水平低于治疗前(P<0.05);研究组治疗12周PMS患者血清E2水平高于对照组,而PMS患者FSH和LH水平低于对照组(P<0.05)。两组治疗前PMS患者性生活症状、生理状态、心理状态和血管舒缩症状评分比较无明显差异(P>0.05);两组治疗12周PMS患者性生活症状、生理状态、心理状态和血管舒缩症状评分低于治疗前(P<0.05);研究组治疗12周PMS患者性生活症状、生理状态、心理状态和血管舒缩症状评分低于对照组(P<0.05)。结论:定坤丹联合芬吗通对PMS患者治疗疗效显著,且可改善患者性激素水平,提高患者生活质量,减轻患者围绝经期症状。

Objective:To explore the therapeutic effect of Dingkun Dan combined with femoston on perimenopausal syndrome(PMS)patients and its effect on sex hormone levels.Methods:102 patients with PMS admitted to our hospital from January 2020 to December 2021 were divided into the control group(n=51)and the study group(n=51).The control group was given femoston tablet 1 tablet/time,once a day,for 4 weeks as a course of treatment.The red tablet was taken orally once a day for the first 14 days,and the yellow tablet was taken orally for the following 14 days.Based on the control group,the study group was given Dingkun Dan orally,twice a day,1/2 pill each time.The treatment period for both groups was 12 weeks.The therapeutic effects,Pittsburgh sleep quality index(PSQI),Kupperman menopause index(KMI),sex hormone levels,and perimenopausal quality of life scale(MENQOL)scores before and 12 weeks after treatment in both groups were compared.Results:The total effective rate of PMS patients in the study group was higher than that in the control group(P<0.05).There were no significant differences in PSQI scores and KMI scores between the two groups before treatment(P>0.05).The PSQI scores and KMI scores of PMS patients in two groups after 12 weeks of treatment were lower than before(P<0.05).PSQI and KMI scores of PMS patients in the study group were lower than those in the control group after 12 weeks of treatment(P<0.05).There were no significant differences in serum estradiol(E2),follicle-stimulating hormone(FSH),and luteinizing hormone(LH)levels between the two groups before treatment(P>0.05).After 12 weeks of treatment,serum E2 levels in PMS patients were higher than before treatment,while FSH and LH levels in PMS patients were lower than before treatment(P<0.05).After 12 weeks of treatment,serum E2 levels in PMS patients in the study group were higher than those in the control group,while FSH and LH levels in PMS patients were lower than those in the control group(P<0.05).There were no significant differences in sexual life symptoms,physiological state,psychological state,and vasomotor symptom scores between the two groups before treatment(P>0.05).After 12 weeks of treatment,sexual life symptoms,physiological status,psychological status,and vasomotor symptom scores of PMS patients in the two groups were lower than before treatment(P<0.05).The sexual life symptoms,physiological status,psychological status,and vasomotor symptom scores of PMS patients in the study group were lower than those in the control group after 12 weeks of treatment(P<0.05).Conclusion:Dingkun Dan combined with femoston has a significant therapeutic effect on PMS patients and can improve the level of sex hormones,improve the quality of life of patients,and reduce perimenopausal symptoms of patients.